CrossrefInfokarte
Impact of Dupilumab on Bone Mineralization Biomarker and Growth Metrics in Children Aged 2 to Under 12 Years With Moderate-to-Severe Atopic Dermatitis
SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s843
DOI: 10.25251/6zq76e36 ↗Abstract
Objective: To assess the effects of dupilumab on serum T-ALP levels (as a proxy for bone mineralization) and height among children aged 2 to
EUVIMED